The CRISPR Journal
Volume 3, Issue 3 / June 2020
https://www.liebertpub.com/toc/crispr/3/3

Perspective Free
What Do We (Not) Know About Global Views of Human Gene Editing? Insights and Blind Spots in the CRISPR Era
Emily L. Howell, Shiyu Yang, Becca Beets, Dominique Brossard, Dietram A. Scheufele, and
Michael A. Xenos
Pages:148–155
Published Online:17 June 2020
Abstract
As research on human applications of CRISPR advances, researchers, advisory bodies, and other stakeholder organizations continue calling for global public discourses and engagement to shape the development of human gene editing (HGE). Research that captures public views and tests ways for engaging across viewpoints is vital for facilitating these discourses. Unfortunately, such research lags behind advances in HGE research and applications. Here, we provide the first review of nationally representative public-opinion surveys focused on HGE to discuss limitations and remaining gaps, illustrating how these gaps hinder interpretation of existing studies. Rigorous research with proper methods for capturing representative public opinion of HGE is limited, especially in countries outside of the United States and on a global scale. The result is severely restricted understanding of even the surface level of public views concerning HGE. We identify broad areas where we need more and better research capturing public views, and describe how future surveys can help collect insights necessary for discourse and decision making on HGE.

Gates Open Research
https://gatesopenresearch.org/browse/articles
[Accessed 20 June 2020]

Research Article metrics AWAITING PEER REVIEW
COVID-19: Identifying countries with indicators of success in responding to the outbreak [version 1; peer review: awaiting peer review]
David S. Kennedy, VK Vu, Hannah Ritchie, Rebecca Bartlein, Oliver Rothschild, Daniel G. Bausch, Max Roser, Anna C. Seale
Peer Reviewers Invited
PUBLISHED 18 Jun 2020

Global Public Health
Volume 15, 2020 Issue 7
http://www.tandfonline.com/toc/rgph20/current

Article
Protecting health during COVID-19 and beyond: A global examination of paid sick leave design in 193 countries*
Jody Heymann , Amy Raub , Willetta Waisath , Michael McCormack , Ross Weistroffer , Gonzalo Moreno , Elizabeth Wong & Alison Earle
Pages: 925-934
Published online: 12 May 2020

Global Public Health
Volume 15, 2020 Issue 7
http://www.tandfonline.com/toc/rgph20/current

Article Commentary
COVID-19 reveals weak health systems by design: Why we must re-make global health in this historic moment
Sriram Shamasunder , Seth M. Holmes , Tinashe Goronga , Hector Carrasco , Elyse Katz , Raphael Frankfurter & Salmaan Keshavjee
Pages: 1083-1089
Published online: 30 Apr 2020

Human Gene Therapy
Volume 31, Issue 11-12 / June 2020
https://www.liebertpub.com/toc/hum/31/11-12

Commentary Free
The Impact of the COVID-19 Pandemic on the Biotech Industry
Philip Reilly
Pages:608–609
Published Online:18 May 2020
… In 2021, the biotech sector will have a valuation at or above the valuation it had in late 2019. Preclinical work will be robust. Clinical trials will be near the volume of a year earlier. The regulatory review of clinical trials will be more efficient. New biotech companies will raise needed capital, and the number of new IPOs will not be much different than in 2019. There will be an uptick in M&A activity as large pharmaceutical companies acquire smaller companies (for example, the decision announced by Alexion on May 5 that it would acquire Portola at a valuation much below that company’s value in mid-2019). Most important, the contributions of talented scientists both inside academe and in the industry will continue to initiate discovery programs, many of which will lead to new drugs in our endless battle against disease.

Infectious Diseases of Poverty
http://www.idpjournal.com/content
[Accessed 20 June 2020]

Mozambique’s response to cyclone Idai: how collaboration and surveillance with water, sanitation and hygiene (WASH) interventions were used to control a cholera epidemic
Cyclone Idai, which hit Mozambique in March 2019, was one of the worst climate-related natural disasters on record in the Southern Hemisphere causing massive destruction of housing and disruption to vital infr…
Authors: Joaquim Domingos Lequechane, Arlete Mahumane, Falume Chale, Crescêncio Nhabomba, Cristolde Salomão, Clemente Lameira, Sérgio Chicumbe and Cynthia Semá Baltazar
Citation: Infectious Diseases of Poverty 2020 9:68
Content type: Letter to the Editor
Published on: 16 June 2020

International Journal of Human Rights in Healthcare
Volume 13 Issue 3 2020
https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/2

Table of Contents
Patients’ rights and professional conduct issues in hospitals’ codes of ethics
Ebru Saygili, Yucel Ozturkoglu
The purpose of this study is to explore the presence of ethical standards in the content of international hospitals codes of ethics disclosed in their websites.

International Journal of Human Rights in Healthcare
Volume 13 Issue 3 2020
https://www.emerald.com/insight/publication/issn/2056-4902/vol/13/iss/2

Table of Contents
Patients’ rights and professional conduct issues in hospitals’ codes of ethics
Ebru Saygili, Yucel Ozturkoglu
The purpose of this study is to explore the presence of ethical standards in the content of international hospitals codes of ethics disclosed in their websites.

International Journal of Infectious Diseases
June 2020 Volume 95, p1-480
https://www.ijidonline.com/issue/S1201-9712(20)X0007-5

Coronavirus (COVID-19) Collection
Positive effects of COVID-19 control measures on influenza prevention
Di Wu, Jianyun Lu, Yanhui Liu, Zhoubin Zhang, Lei Luo
p345–346
Published online: April 10, 2020

International Journal of Infectious Diseases
June 2020 Volume 95, p1-480
https://www.ijidonline.com/issue/S1201-9712(20)X0007-5

Perspective
Can cholera ‘hotspots’ be converted to cholera ‘coldspots’ in cholera endemic countries? The Matlab, Bangladesh experience
K. Zaman, Deok Ryun Kim, Mohammad Ali, Faisal Ahmmed, Justin Im, Md Taufiqul Islam, Ashraful Islam Khan, Md Yunus, Md Alfazal Khan, Florian Marks, Firdausi Qadri, Jerome Kim, John D. Clemens
p28–31
Published online: February 29, 2020

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

Viewpoint
Emergency Use Authorization of Remdesivir- The Need for a Transparent Distribution Process
Michael G. Ison, MD, MS; Cameron Wolfe, MBBS, MPH; Helen W. Boucher, MD
JAMA. 2020;323(23):2365-2366. doi:10.1001/jama.2020.8863
This Viewpoint reviews the FDA’s May 2020 Emergency Use Authorization of the antiviral drug remdesivir for treatment of COVID-19 and discusses the need for a transparent distribution plan of a drug not otherwise available in the US and for which demand will likely exceed supply.

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

An Ethical Framework for Allocating Scarce Inpatient Medications for COVID-19 in the US
Colette DeJong, MD; Alice Hm Chen, MD, MPH; Bernard Lo, MD
free access has active quiz
JAMA. 2020;323(23):2367-2368. doi:10.1001/jama.2020.8914
This Viewpoint proposes ethical principles to guide allocation of scarce inpatient therapies for hospitalized COVID-19 patients to maximize patient benefit, mitigate disparities, and minimize clinician burden.

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

Using Controlled Trials to Resolve Key Unknowns About Policy During the COVID-19 Pandemic
Paul Starr, PhD
free access has multimedia has audio
JAMA. 2020;323(23):2369-2370. doi:10.1001/jama.2020.8573
This Viewpoint proposes implementing comparison groups for policy decisions, for example assessing disease transmission with alternative housing vs in-home isolation of individuals who test positive for coronavirus disease 2019 (COVID-19), or with different durations or cycles of school openings, to gather data that could make broader and future policy implementations more informed and effective.
Audio Interview: Coronavirus Q&A: Managing the Pandemic

JAMA
June 9, 2020, Vol 323, No. 22, Pages 2231-2350
https://jamanetwork.com/journals/jama/currentissue

Editorial
Randomized Clinical Trials and COVID-19 – Managing Expectations
Howard Bauchner, MD; Phil B. Fontanarosa, MD, MBA

JBI Database of Systematic Review and Implementation Reports
June 2020 – Volume 18 – Issue 6
https://journals.lww.com/jbisrir/Pages/currenttoc.aspx

EDITORIAL
COVID-19 and One Health: shifting the paradigm in how we think about health
Henley, Phaedra
JBI Evidence Synthesis. 18(6):1154-1155, June 2020.

The Lancet
Jun 20, 2020 Volume 395 Number 10241 p1883-1948, e107-e111
https://www.thelancet.com/journals/lancet/issue/current

Editorial
Global governance for COVID-19 vaccines
The Lancet
[See Milestones/Perspectives above for full text]

The Lancet
Jun 20, 2020 Volume 395 Number 10241 p1883-1948, e107-e111
https://www.thelancet.com/journals/lancet/issue/current

Comment
The right to health must guide responses to COVID-19
Dainius Pūras, Judith Bueno de Mesquita, Luisa Cabal, Allan Maleche, Benjamin Mason Mei

The Lancet
Jun 20, 2020 Volume 395 Number 10241 p1883-1948, e107-e111
https://www.thelancet.com/journals/lancet/issue/current

Articles
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Nicole M Kuderer, on behalf of the COVID-19 and Cancer Consortium
Interpretation
Among patients with cancer and COVID-19, 30-day all-cause mortality was high and associated with general risk factors and risk factors unique to patients with cancer. Longer follow-up is needed to better understand the effect of COVID-19 on outcomes in patients with cancer, including the ability to continue specific cancer treatments.

Lancet Respiratory Medicine
Jun 2020 Volume 8 Number 6 p527-646, e43-e54
http://www.thelancet.com/journals/lanres/issue/current

Comment
Influenza immunisation in pregnancy is efficacious and safe, but questions remain
Paul Loubet, Vassilis Tsatsaris, Odile Launay

Lancet Respiratory Medicine
Jun 2020 Volume 8 Number 6 p527-646, e43-e54
http://www.thelancet.com/journals/lanres/issue/current

Tackling two pandemics: a plea on World Tuberculosis Day
Tom Wingfield, Luis E Cuevas, Peter MacPherson, Kerry A Millington, S Bertel Squire

Lancet Respiratory Medicine
Jun 2020 Volume 8 Number 6 p527-646, e43-e54
http://www.thelancet.com/journals/lanres/issue/current

Articles
Efficacy, duration of protection, birth outcomes, and infant growth associated with influenza vaccination in pregnancy: a pooled analysis of three randomised controlled trials
Saad B Omer,et al. for the BMGF Supported Maternal Influenza Immunization Trials Investigators Group
Open Access
Maternal influenza immunisation can reduce morbidity and mortality associated with influenza infection in pregnant women and young infants. We aimed to determine the vaccine efficacy of maternal influenza immunisation against maternal and infant PCR-confirmed influenza, duration of protection, and the effect of gestational age at vaccination on vaccine efficacy, birth outcomes, and infant growth up to 6 months of age…
Interpretation
The assessment of efficacy for women vaccinated before 29 weeks gestational age might have been underpowered, because the point estimate suggests that there might be efficacy despite wide CIs. Estimates of efficacy against PCR-confirmed influenza and safety in terms of adverse birth outcomes should be incorporated into any further consideration of maternal influenza immunisation recommendations.

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy

Volume 98, Issue 2 Pages: 223-617 June 2020
https://onlinelibrary.wiley.com/toc/14680009/current
Original Scholarship
Open Access
Can Social Policies Improve Health? A Systematic Review and Meta‐Analysis of 38 Randomized Trials
EMILIE COURTIN. SOOYOUNG KIM, SHANSHAN SONG, WENYA YU, PETER MUENNIG
Pages: 297-371
First Published: 19 March 2020
Policy Points
:: Social policies might not only improve economic well‐being, but also health. Health policy experts have therefore advocated for investments in social policies both to improve population health and potentially reduce health system costs.
:: Since the 1960s, a large number of social policies have been experimentally evaluated in the United States. Some of these experiments include health outcomes, providing a unique opportunity to inform evidence‐based policymaking.
:: Our comprehensive review and meta‐analysis of these experiments find suggestive evidence of health benefits associated with investments in early life, income support, and health insurance interventions. However, most studies were underpowered to detect health outcomes.

Nature Medicine
Volume 26 Issue 6, June 2020
https://www.nature.com/nm/volumes/26/issues/6

Editorial | 04 June 2020
It is not the time for science fiction
Government officials who disseminate unsupported claims about the novel coronavirus undermine public trust in science and in the public-health efforts that are essential to bringing the COVID-19 pandemic under control.

Nature Medicine
Volume 26 Issue 6, June 2020
https://www.nature.com/nm/volumes/26/issues/6

World View | 07 May 2020
Protect against market exclusivity in the fight against COVID-19
Patents and other intellectual properties could slow down the scale-up and accessibility of treatments and vaccines against COVID-19.
Ellen ’t Hoen

Nature Medicine
Volume 26 Issue 6, June 2020
https://www.nature.com/nm/volumes/26/issues/6

Perspective | 11 June 2020
Ten recommendations for supporting open pathogen genomic analysis in public health
To support progress in genomic epidemiology, a transparent, user-friendly approach is required.
Allison Black, Duncan R. MacCannell […]  & Trevor Bedford
Abstract
Increasingly, public-health agencies are using pathogen genomic sequence data to support surveillance and epidemiological investigations. As access to whole-genome sequencing has grown, greater amounts of molecular data have helped improve the ability to detect and track outbreaks of diseases such as COVID-19, investigate transmission chains and explore large-scale population dynamics, such as the spread of antibiotic resistance. However, the wide adoption of whole-genome sequencing also poses new challenges for public-health agencies that must adapt to support a new set of expertise, which means that the capacity to perform genomic data assembly and analysis has not expanded as widely as the adoption of sequencing itself. In this Perspective, we make recommendations for developing an accessible, unified informatic ecosystem to support pathogen genomic analysis in public-health agencies across income settings. We hope that the creation of this ecosystem will allow agencies to effectively and efficiently share data, workflows and analyses and thereby increase the reproducibility, accessibility and auditability of pathogen genomic analysis while also supporting agency autonomy.

New England Journal of Medicine
June 18, 2020 Vol. 382 No. 25
http://www.nejm.org/toc/nejm/medical-journal

Clinical Implications of Basic Research
Amplifying RNA Vaccine Development
Deborah H. Fuller, Ph.D., and Peter Berglund, Ph.D.
… With the emergence of the Covid-19 pandemic, an mRNA vaccine was the first to enter clinical trials, with the first volunteers receiving the vaccine within 10 weeks after the genetic sequence of SARS-CoV-2 was released (www.modernatx.com/modernas-work-potential-vaccine-against-covid-19. opens in new tab). Nucleic acid vaccines are now a major hope for solving this pandemic crisis. This comes as no surprise. From their earliest conception, nucleic acid vaccines were recognized as a possible solution for a rapid pandemic response. The need for only the sequence of a pathogen in order to generate the vaccine and its simplicity in manufacture have long been recognized as superpowers in nucleic acid vaccines with regard to the delivery of a rapid response to an emerging epidemic. The ability of self-amplifying RNA vaccines, and now trans-amplifying RNA vaccines, to provide amplified and durable production of antigen in vivo, coupled with potent inherent innate immune-stimulating properties, adds to these powers and may provide the dose-sparing (i.e., getting the same immune responses with smaller doses of vaccine) that will probably be needed to meet global demands. We can only hope that their deployment will render the Covid-19 pandemic crisis into a more manageable challenge, saving lives and decreasing morbidity.

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 20 June 2020)

Antibiotic prescription practices in primary care in low- and middle-income countries: A systematic review and meta-analysis
Giorgia Sulis, Pierrick Adam, Vaidehi Nafade, Genevieve Gore, Benjamin Daniels, Amrita Daftary, Jishnu Das, Sumanth Gandra, Madhukar Pai
Research Article | published 16 Jun 2020 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003139

PLoS Medicine
http://www.plosmedicine.org/
(Accessed 20 June 2020)

The potential impact of COVID-19 in refugee camps in Bangladesh and beyond:  A modeling study
Shaun Truelove, Orit Abrahim, Chiara Altare, Stephen A. Lauer, Krya H. Grantz, Andrew S. Azman, Paul Spiegel
Research Article | published 16 Jun 2020 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003144

PLoS Neglected Tropical Diseases
http://www.plosntds.org/
(Accessed 20 June 2020)

Social marketing interventions for the prevention and control of neglected tropical diseases: A systematic review
Nathaly Aya Pastrana, Maria Lazo-Porras, J. Jaime Miranda, David Beran, L. Suzanne Suggs
Research Article | published 17 Jun 2020 PLOS Neglected Tropical Diseases
https://doi.org/10.1371/journal.pntd.0008360

PLoS One
http://www.plosone.org/
[Accessed 20 June 2020]

Recruiters’ perspectives of recruiting women during pregnancy and childbirth to clinical trials: A qualitative evidence synthesis
Vivienne Hanrahan, Katie Gillies, Linda Biesty
Research Article | published 19 Jun 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0234783

PLoS One
http://www.plosone.org/
[Accessed 20 June 2020]

Seasonal influenza vaccination in older people: A systematic review and meta-analysis of the determining factors
George N. Okoli, Otto L. T. Lam, Florentin Racovitan, Viraj K. Reddy, Christiaan H. Righolt, Christine Neilson, Ayman Chit, Edward Thommes, Ahmed M. Abou-Setta, Salaheddin M. Mahmud
Research Article | published 18 Jun 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0234702

PLoS One
http://www.plosone.org/
[Accessed 20 June 2020]

A hidden vulnerable population: Young children up-to-date on vaccine series recommendations except influenza vaccines
William K. Bleser, Daniel A. Salmon, Patricia Y. Miranda
Research Article | published 18 Jun 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0234466

PLoS One
http://www.plosone.org/
[Accessed 20 June 2020]

Improving measles vaccine uptake rates in Nigeria: An RCT evaluating the impact of incentive sizes and reminder calls on vaccine uptake
Steven Brownstone, Alison Connor, Daniel Stein

Research Article | published 18 Jun 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0233149

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/

Economic and social consequences of human mobility restrictions under COVID-19
Giovanni Bonaccorsi, Francesco Pierri, Matteo Cinelli, Andrea Flori, Alessandro Galeazzi, Francesco Porcelli, Ana Lucia Schmidt, Carlo Michele Valensise, Antonio Scala, Walter Quattrociocchi, and Fabio Pammolli
PNAS first published June 18, 2020. https://doi.org/10.1073/pnas.2007658117

PNAS – Proceedings of the National Academy of Sciences of the United States of America
http://www.pnas.org/content/early/

Vaccination as a social contract
Lars Korn, Robert Böhm, Nicolas W. Meier, and Cornelia Betsch
PNAS first published June 15, 2020. https://doi.org/10.1073/pnas.1919666117

Risk Analysis
Volume 40, Issue 6 Pages: 1111-1319 June 2020
https://onlinelibrary.wiley.com/toc/15396924/current

Original Research Articles
Understanding Risk Information Seeking and Processing during an Infectious Disease Outbreak: The Case of Zika Virus
Austin Y. Hubner, Shelly R. Hovick
Pages: 1212-1225
First Published: 17 February 2020

Science
19 June 2020 Vol 368, Issue 6497
http://www.sciencemag.org/current.dtl

In Depth
Pandemic vaccines are about to face the real test
By Jon Cohen
Science19 Jun 2020 : 1295-1296 Full Access
U.S. and global efforts are taking different approaches to key efficacy trials of candidates.
Summary
A Chinese company will turn to Brazil for help. The World Health Organization is adopting a strategy forged in a war zone during an Ebola outbreak. And the Trump administration plans to lean on existing infrastructure for testing HIV and flu vaccines. These are the disparate strategies about to be employed in the next and most important stage of the COVID-19 vaccine race: the large-scale, placebo-controlled, human trials needed to prove which of the more than 135 candidates are safe and effective.

Social Science & Medicine
Volume 253 May 2020
https://www.sciencedirect.com/journal/social-science-and-medicine/vol/253/suppl/C

Research article Open access
Social, ethical, and other value judgments in health economics modelling
Stephanie Harvard, Gregory R. Werker, Diego S. Silva
Article 112975
Highlights
:: Interviews with health economists reinforced philosophical arguments positing a role for values throughout research.
:: Values informed early modelling decisions, model assumptions, and trade-offs between
:: Values played a role in assessing consequences of error and taking action under uncertainty in the modelling process.
Abstract
Modelling is a major method of inquiry in health economics. In other modelling-intensive fields, such as climate science, recent scholarship has described how social and ethical values influence model development. However, no similar work has been done in health economics. This study explored the role of social, ethical, and other values in health economics modelling using philosophical theory and qualitative interviews in British Columbia, Canada. Twenty-two professionals working in health economics modelling were interviewed between February and May, 2019. The study findings provide support for four philosophical arguments positing an essential role for social and ethical values throughout scientific inquiry and demonstrate how these arguments apply to health economics modelling. It highlights the role of social values in informing early modelling decisions, shaping model assumptions, making trade-offs between desirable model features, and setting standards of evidence. These results point to several decisions in the modelling process that warrant focus in future health economics research, particularly that which aims to incorporate patient and public values.

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Conference info Abstract only
Preparing to introduce new maternal immunizations in low- and lower-middle-income countries: A report from the Bill & Melinda Gates Foundation convening “Allies in Maternal and Newborn Care”; May 3–4, 2018
Ajoke Sobanjo-ter Meulen, Jerker Liljestrand, Joy E. Lawn, Joachim Hombach, … Keith P. Klugman
Pages 4355-4361

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Discussion Open access
Gonococcal vaccines: Public health value and preferred product characteristics; report of a WHO global stakeholder consultation, January 2019
Sami L. Gottlieb, Francis Ndowa, Edward W. Hook, Carolyn Deal, … Birgitte K. Giersing
Pages 4362-4373

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Research article No access
Electronic immunization registers – A tool for mitigating outbreaks of vaccine-preventable diseases in the Pacific
Meru Sheel, Ashley Tippins, Kathryn Glass, Martyn Kirk, Colleen L. Lau
Pages 4395-4398

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Research article Abstract only
Routine immunization coverage in Pakistan: a survey of children under 1 year of age in community-based vaccination areas
Meghana Sreevatsava, Ashley L. Burman, Ashraf Wahdan, Rana M. Safdar, … Jamal Ahmed
Pages 4399-4404

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Research article Abstract only
The contagious nature of a vaccine scare: How the introduction of HPV vaccination lifted and eroded MMR vaccination in Denmark
Mette Gørtz, Noel T. Brewer, Peter Reinhard Hansen, Mette Ejrnæs
Pages 4432-4439

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Research article Abstract only
Routine immunization coverage in Pakistan: a survey of children under 1 year of age in community-based vaccination areas
Meghana Sreevatsava, Ashley L. Burman, Ashraf Wahdan, Rana M. Safdar, … Jamal Ahmed
Pages 4399-4404

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Research article Abstract only
The contagious nature of a vaccine scare: How the introduction of HPV vaccination lifted and eroded MMR vaccination in Denmark
Mette Gørtz, Noel T. Brewer, Peter Reinhard Hansen, Mette Ejrnæs
Pages 4432-4439

Vaccine
Volume 38, Issue 28 Pages 4355-4506 (9 June 2020)
https://www.sciencedirect.com/journal/vaccine/vol/38/issue/28

Research article Abstract only
Immunizations at Wisconsin Pharmacies: Results of a statewide vaccine registry analysis and pharmacist survey
Philip C. Berce, Rebecca S. Bernstein, George E. MacKinnon, Sarah Sorum, … Kenneth G. Schellhase
Pages 4448-4456

Special Section on “Future of Vaccine Development”; Edited by W. Koff and T. Schenkelberg
Research article Abstract only

The future of vaccine development
Wayne C. Koff, Theodore Schenkelberg
Pages 4485-4486
Abstract
Vaccines are one of the most successful public health interventions in our history resulting in eradication of small pox, near eradication of polio and major reductions in case number and global morbidity and mortality for numerous diseases (Centers for Disease C, 1999) [1]. However, vaccine development has been less successful against complex infectious diseases, where pathogen variability and/or immune evasion mechanisms have combined to pose major obstacles, and have been unsuccessful against non-communicable diseases, including cancer, autoimmunity, allergy, neurodegenerative and metabolic diseases (Koff et al., 2013) [2]. In addition, the current state of vaccine development is an expensive, slow and laborious process, costing billions of dollars, taking decades, with less than a 10% rate of success (Pronker et al., 2013) [3]. While some vaccines, such as the smallpox vaccine approach the gold standard of life-long protection in everyone following a single immunization, other vaccines are less effective, often requiring multiple immunizations, being less effective to populations most susceptible to disease such as infants, the elderly, and those living in the developing world. There is clearly an urgent need to determine ways to improve not just the effectiveness of the vaccines themselves but also the very processes by which they are developed.

Vaccines — Open Access Journal
http://www.mdpi.com/journal/vaccines
(Accessed 20 June 2020)

Open Access Article
Trends, Coverage and Influencing Determinants of Influenza Vaccination in the Elderly: A Population-Based National Survey in Spain (2006–2017)
by Silvia Portero de la Cruz and Jesús Cebrino
Vaccines 2020, 8(2), 327; https://doi.org/10.3390/vaccines8020327 – 19 Jun 2020
Abstract
Influenza is a significant public health problem and the elderly are at a greater risk of contracting the disease. The vaccination coverage of the elderly is below the Spanish target of 65% for each influenza season. The aims of this study were to report the coverage of influenza vaccination in Spain among the population aged ≥65 years and high-risk groups for suffering chronic diseases, to analyze the time trends from 2006 to 2017 and to identify the factors which affect vaccination coverage. A nationwide cross-sectional study was conducted including 20,753 non-institutionalized individuals aged ≥65 years who had participated in the Spanish National Health Surveys in 2006, 2011/2012, and 2017. Sociodemographic, health-related variables, and influenza vaccination data were used. A logistic regression analysis was performed to determine the variables associated with influenza vaccination. Influenza vaccination coverage was 60%. By chronic condition, older people with high cholesterol levels and cancer had the lowest vaccination coverage (62.41% and 60.73%, respectively). This coverage declined from 2006 to 2017 in both groups. Higher influenza vaccination was associated with males, Spanish nationality, normal social support perceived, polypharmacy, worse perceived health, participation in other preventive measures, and increasing age and the number of chronic diseases.

Value in Health
June 2020 Volume 23, Issue 6, p677-826
https://www.valueinhealthjournal.com/issue/S1098-3015(20)X0008-8

ISPOR REPORT
Defining Patient Engagement in Research: Results of a Systematic Review and Analysis: Report of the ISPOR Patient-Centered Special Interest Group
Rachel L. Harrington, Maya L. Hanna, Elisabeth M. Oehrlein, Rob Camp, Russell Wheeler, Clarissa Cooblall, Theresa Tesoro, Amie M. Scott, Rainald von Gizycki, Francis Nguyen, Asha Hareendran, Donald L. Patrick, Eleanor M. Perfetto
p677–688
Published online: May 23, 2020

From Google Scholar & other sources: Selected Journal Articles, Newsletters, Dissertations, Theses, Commentary

No new digest content identified.